NCT01738191View on ClinicalTrials.gov

Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Parkinson's DiseaseCognitive Impairment
Interventions
DRUG

Atomoxetine

The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.

DRUG

Placebo

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

lead

Medical University of South Carolina

OTHER

NCT01738191 - Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog) | Biotech Hunter | Biotech Hunter